Market open
aTyr Pharma/$ATYR
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Ticker
$ATYR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
61
ISIN
US0021202025
Website
aTyr Pharma Metrics
BasicAdvanced
$267M
-
-$0.80
0.79
-
Price and volume
Market cap
$267M
Beta
0.79
52-week high
$4.66
52-week low
$1.42
Average daily volume
1.3M
Financial strength
Current ratio
7.795
Quick ratio
7.239
Long term debt to equity
15.629
Total debt to equity
17.352
Management effectiveness
Return on assets (TTM)
-39.82%
Return on equity (TTM)
-79.70%
Valuation
Price to book
3.56
Price to tangible book (TTM)
3.56
Price to free cash flow (TTM)
-3.827
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-11.62%
3-year earnings per share growth (CAGR)
-22.59%
What the Analysts think about aTyr Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
aTyr Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
aTyr Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
aTyr Pharma News
AllArticlesVideos
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
GlobeNewsWire·2 days ago
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
GlobeNewsWire·1 week ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for aTyr Pharma stock?
aTyr Pharma (ATYR) has a market cap of $267M as of May 16, 2025.
What is the P/E ratio for aTyr Pharma stock?
The price to earnings (P/E) ratio for aTyr Pharma (ATYR) stock is 0 as of May 16, 2025.
Does aTyr Pharma stock pay dividends?
No, aTyr Pharma (ATYR) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next aTyr Pharma dividend payment date?
aTyr Pharma (ATYR) stock does not pay dividends to its shareholders.
What is the beta indicator for aTyr Pharma?
aTyr Pharma (ATYR) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.